ICICI Pru Pharma Fund Surges: 3-Year CAGR Leads Sector, Outperforms Benchmark by Double-Digit Margins

ICICI Pru Pharma Fund Surges: 3-Year CAGR Leads Sector, Outperforms Benchmark by Double-Digit Margins​

ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund has emerged as the top performer among specialized pharmaceutical and healthcare sectoral mutual funds. According to data from June 24, the fund delivered a remarkable 26.5 percent return over three years, establishing clear dominance in this focused investment category.

The performance highlights ICICI Pru's ability to capitalize on specific industry trends. The P.H.D Fund maintained significant superiority over competitors like SBI Healthcare Opp Fund (24.5 percent) and Mirae Asset Healthcare Fund (24.0 percent), all within the cohort of funds meeting established investment criteria.

Performance Metrics in Pharma & Healthcare Sector Funds​

The ranking, which restricts comparison to schemes with assets under management exceeding Rs 1,500 crore, paints a picture of strong sustained returns for the ICICI Pru fund. This performance was further solidified by its benchmark outperformance over both the three-year and one-year horizons.

Over three years, the P.H.D Fund exceeded its assigned benchmark return by a substantial 16.5 percentage points. The benchmark fund itself returned 10.0 percent during this period. Similarly, in the last year, the ICICI Pru fund was ahead of its benchmark by 13.3 percentage points, while the benchmark registered a negative return of -2.9 percent.

Dynamics Across Various Investment Windows​

The performance analysis across different timeframes shows that sector-specific leadership is dynamic and varies greatly depending on the period assessed. While ICICI Pru maintains a commanding lead over the long term, other funds have shown specialized strengths in shorter cycles.

For instance, when reviewing the one-month snapshot, SBI Healthcare Opp Fund led the peer group with a return of 4.0 percent. Looking at the three-month horizon, DSP Healthcare Fund demonstrated the strongest performance among the five assessed schemes, posting a 17.8 percent gain.

Sectoral Trends and AUM Landscape​

The data reflects a healthy ecosystem within the pharmaceutical and healthcare sector mutual fund space. Nippon India Pharma Fund stands out as holding the largest assets under management (AUM) among the top performers at Rs 8,635.7 crore. This indicates significant institutional confidence in the growth trajectory of the Indian pharma sector.

The concentrated nature of sectoral funds means that their performance is tightly linked to a narrow investment universe. While this concentration increases risk, it also allows for sharp gains when the underlying industry performs strongly, as demonstrated by the ICICI Pru fund's high three-year CAGR.

Summary of Top Pharma & Healthcare Funds​

While ICICI Pru leads the long-term race, the table provides granular insights into the current landscape. The five leading funds—ICICI Pru P.H.D Fund, SBI Healthcare Opp Fund, Mirae Asset Healthcare Fund, DSP Healthcare Fund, and Nippon India Pharma Fund—all exhibit robust performance across multiple time horizons.

The collective figures underscore that sector-specific investing remains a high-stakes area, rewarding those who can successfully navigate the complexities of industry cycles for sustained returns.